DDInter1610 DDInter233
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Rivastigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Alectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alectinib
Alectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Physostigmine
Physostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Rivastigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) resembles Neostigmine (Compound) and Neostigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Rivastigmine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib